Clinical Trial Update: A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating subcutaneous AK002 for eosinophilic gastritis and/or eosinophilic duodenitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Duodenitis
• Eosinophilic Gastritis

Drugs mentioned

• AK002 (AK002)

Snippet

Sponsor: Allakos Inc. | Conditions: Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Status: WITHDRAWN